Schering anesthesia med makes Euro-debut

Schering-Plough has launched its anesthesia-reversal drug Bridion in Sweden, with plans to inaugurate the drug in the U.K. and Germany soon. Known generically as sugammadex, the drug was rejected for U.S. sale by the FDA in August, on concerns about allergic reactions. The agency said it may ask for more data on those reactions. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.